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Introduction
The goal of radical prostatectomy is complete removal of all cancer cells. Unfortunately, even in carefully selected patients, up to two-thirds of clinically con®ned tumors are understaged, and positive margin rates of 30 ± 60% are reported following radical prostatectomy. 1 ± 3 Although higher tumor stage, grade and pre-operative serum prostate speci®c antigen (PSA) levels correlate with higher pathologic stage and risk of disease recurrence, prognostic variables are limited in their ability to independently and individually predict pathologic stage and risk of recurrence. 4 ± 6 In order to optimize outcomes from radical prostatectomy, only men with low-risk tumors (T 1 or T 2a , Gleason score`6, serum PSA`10 mg/l) have traditionally been considered ideal for cure by surgical intervention. Thus, ideal candidates for radical prostatectomy are men with the highest probability of being cured by the operation. Indeed, cure rates following radical prostatectomy alone exceed 80% in men with low-risk tumors. 7, 8 However, radical therapy may represent overtreatment in some of these men because of the indolent natural history of low-risk disease. 9 In contrast, most men with high-risk localized tumors (b T 2b , Gleason score 7, PSA b 10 mg/l) and life expectancies b 10 y will die of their disease if they are not treated with curative intent. 9 High-risk tumors exhibit a more aggressive natural history and have higher positive margin and recurrence rates after radical prostatectomy or radiotherapy alone, where unimodality therapy probably represents undertreatment. 4 ± 9 Paradoxically, the therapeutic ratio (patients who actually realize a survival bene®t from a therapeutic intervention) may therefore be greater in high-risk disease if its natural history can be altered by multimodality therapy. It is important, therefore, to investigate therapies that optimize complete extirpation of all cancer cells and reduce the incidence of positive surgical margins and disease recurrence.
The term adjuvant therapy refers to the use of systemic therapy after management of localized disease when risk of recurrence is known to be high. Chemotherapy regimens can cure some patients when used adjuvantly even though the same regimen fails to alter the natural history of established metastatic disease. Experimental animal model and early clinical trial data suggest that administration of systemic therapy is more likely to affect cure when tumor burden is low. 10 Neoadjuvant therapy extends this logic further by applying systemic therapy earlier in the course of the disease prior to de®nitive locoregional therapy. The aim of neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy is reduction of positive margin rates and ultimately decreased disease recurrence. The role of NHT prior to radical prostatectomy is controversial as some clinicians argue that downsizing occurs without down staging and any apparent down staging results from dif®culty in pathologic evaluation of the neoadjuvantly treated prostatectomy specimen. 11, 12 Others further argue that short-term follow-up from randomized studies comparing 3 months of NHT to surgery alone show no difference in biochemical recurrence rates. 13 However, NHT has many attractive theoretical features and research in this are is justi®ed and important. The purpose of this article is to review the rationale behind NHT, critique the randomized studies of 3 months of therapy, and examine the optimal duration of therapy.
Rationale behind neoadjuvant therapy prior to radical prostatectomy no prognostic variable exists that can be applied independently and individually to predict pathologic stage. 4 Up to two-thirds of clinically con®ned tumors are understaged, and positive margin rates of 30 ± 60% are reported following radical prostatectomy. 1 ± 3 Incomplete excision places the patient at higher risk of disease recurrence. 5 ± 8 Selection of patients who are most likely to bene®t from NHT remains critical; NHT is less likely to alter outcome in most low-risk tumors (PSA`10 mg/l, Gleason score 6, stage T 1C , since most of these patients do well with surgery alone. In contrast, men with high-risk localized tumors (PSA b 10 mg/l, Gleason grade b 7) are at signi®-cant risk of positive margins and PSA recurrence. Patients with positive margins are often offered post-operative radiation therapy to consolidate local therapy, which is associated with increased risk of urinary incontinence, importance and anastomotic strictures. It is therefore important to investigate combinations of therapies that optimize complete extirpation of all cancer cells and reduce the incidence of positive surgical margins.
Reversible androgen suppression therapy
The development of potent, well-tolerated and reversible agents for androgen ablation therapy provides a safe method for inducing prostate cancer cell death and tumor regression prior to radical prostatectomy. Several classes of drugs induce castrate levels of testosterone through suppression of LH release from the pituitary gland, including diethylstilbestrol (DES) 14 luteinizinghormone-releasing hormone (LHRH) agonists include goserelin, leuprolide and buserelin. 15, 16 The¯are reaction can be prevented by cyproterone acetate or DES 1 week prior to the LHRH analog, or blocked by nonsteroidal anti-androgens like¯utamide or bicalutamide.
Prostate tumor cell death, not just tumor shrinkage, occurs following medical castration. Apoptosis, or programmed cell death, occurs in normal, benign hyperplastic and malignant prostatic epithelial cells by any procedure that results in castrate levels of testosterone. 17 ± 19 Apoptotic cell death appears to be a`genetic suicide' process that requires activation of a series of genes and is characterized morphologically by shrunken cells with condensed and fragmented nuclei (apoptotic bodies). Initiation of apoptosis may, in part, be cell-cycle speci®c or regulated by epigenetic factors and may therefore begin at different times in different populations of cells. Maximal apoptotic regression of ventral rat prostate glands and Shionogi tumors is complete within 1 ± 2 weeks following castration; 19 however, timing of apoptosis has not been well characterized in benign or malignant human prostate tissue and probably takes place over a longer period of time.
Availability of PSA as a marker of tumor regression PSA gene expression is androgen-regulated and serum PSA levels are dependent on both androgen levels and tumor volume. 20, 21 After institution of androgen ablation therapy, serum PSA levels decrease rapidly and dramatically due to cessation of androgen-regulated PSA gene expression and apoptosis. Although signi®cant downsizing occurs after 3 months of therapy, serum PSA does not reach undetectable levels after 3 months in most patients, which suggests that optimal duration of NHT may be longer than 3 months. Maximal tumor regression probably occurs when PSA reaches its nadir level. Changes in serum PSA following NHT provide objective biochemical information that re¯ects tumor response and may identify patients not responding favorably.
Animal model studies
Androgen withdrawal in the Shionogi tumor model precipitates apoptosis and tumor regression in a highly reproducible manner with up to a 2-log cell kill, but despite undergoing complete regression, androgen-independent tumors recur after one month. 19 Conceptually, the ideal time to implement curative therapy is after maximal castration-induced tumor involution but before outgrowth of androgen-resistant clones. Experiments Figure 1 Neoadjuvant castration reduces local recurrence rates in the Shionogi tumor model. Tumors were allowed to grow to 1 ± 2 g before mice were randomized to either tumor excision with wide margins and castration upon tumor recurrence (group 1), or neoadjuvant castration for 10 days followed by wide excision of the regressed tumor (group 2). The study endpoint was androgen-independent tumor recurrence which occurred in 80% of Group 1 after a median of 36 days and 44% of mice in Group 2 after a median of 42 days.
Neoadjuvant hormonal therapy ME Gleave et al 137 designed to determine whether local recurrence rates after tumor excision were lower with neoadjuvant compared to adjuvant androgen ablation demonstrated that tumor-free survival was signi®cantly greater in the NHT group (56% vs 20%, P`0.05; Figure 1 ). 22 Although this model can not address the issue of the affect of NHT on subclinical metastases, extrapolation of these results to the clinical disease suggests that NHT may help to reduce not only the positive margin rates but also the subsequent risk of local recurrence following radical prostatectomy.
Clinical studies with short-term neoadjuvant therapy
Most studies assessing the effects of NHT prior to surgery chose, somewhat empirically, a 3 month duration. Surrogate endpoints for assessing the ef®cacy of NHT prior to radical prostatectomy include serum PSA nadir levels prior to surgery, pathologic stage and positive margin rates, and most importantly, serum PSA recurrence rates following surgery.
Nonrandomized clinical studies
Most nonrandomized studies report decreases in serum PSA, prostatic volume and positive margin rates following 3 months of NHT (Table 1) . These studies do not report on time to PSA nadir or absolute PSA nadir levels. Soloman et al 23 reported on the largest phase II series of 156 patients with T 2 /T 3 tumors treated with between 3 and 6 months of an LHRH agonist plus¯utamide. Positive margin rates were 11.5%, compared to 35% in historical controls, but no postoperative follow-up data has been reported. Investigators at Memorial Sloan Kettering Cancer Center have conducted a series of studies beginning with a report by Aprikian et al 24 which suggested that most patients with locally advanced cT 3 tumors did not bene®t from between 2 and 8 months of neoadjuvant DES. A subsequent phase II study of 141 patients with cT 1 or cT 2 tumors reported signi®cant decreases in serum PSA (b 98%) and a 38% decrease in prostatic volume after 3 months of LHRH agonist with utamide. 25 Pathologic staging revealed increased organcon®ned rates (74% vs 49%) and decreased positive margin rates (10% vs 33%) when compared to a group of 72 concurrent controls who did not receive NHT. However at 48 months follow-up, no differences in PSA recurrence rates were apparent. 26 Several smaller nonrandomized studies by Sassine and Schulman 27, 28 and by Ha È ggman et al 29 also reported 40 ± 50% decreases in positive margin rates when groups of patients pretreated with 3 months of NHT were compared to historical controls. In contrast, reports on small cohorts of patients with cT 2 or cT 3 tumors by Mcfarlane et al 11 and Oesterling et al 12 suggested no improvement in pathologic outcome following short-term NHT. These nonrandomized studies (reviewed in Table 1 ) illustrate that outcome (pathologic stage, positive margin rates, and risk of PSA recurrence) is dependent on many factors, including proportion of T 3 tumors and other high-risk features, length of postoperative follow-up, and time period during which the study accrued (stage migration towards earlier diagnosis began in early 1990s). Conclusions from such studies must be drawn with caution, but taken together the results suggest that 3 months on NHT result in encouraging pathologic effects and lead to initiation of Phase III randomized studies. Neoadjuvant hormonal therapy ME Gleave et al
Randomized clinical studies
To date, seven Phase III randomized studies comparing 0 vs 3 months of NHT have been published (Table 2 ). 30 ± 36 The primary endpoint in all these trials was incidence of positive margin disease. All seven of these studies demonstrate signi®cant decreases in positive surgical margins after 3 months of NHT, reporting decreases ranging from 34 ± 65% to 8 ± 28%. These studies do not report on time to PSA nadir or absolute PSA nadir levels. Soloway et al 31 published the results of a multicenter randomized study comparing 0 vs 3 months of leuprolide and¯utamide prior to radical prostatectomy. Positive margin rates decreased by over 50% from 42% in the control group to 17% in the NHT group. Organ-con®ned disease (pT 2 ) was reported twice as frequently in the NHT group (53%) compared to the surgery alone group (22%). Similarly, a randomized multicenter trial by the Canadian Uro-Oncology Group (CUOG) using 3 months of cyproterone acetate also reported a 50% reduction in positive margin rates (65% vs 28%) and doubling of the organcon®ned rate (20% vs 42%). 33 Fair and Kava 34 reported results of a recent randomized trial comparing 0 vs 3 months of NHT (LHRH plus¯utamide) in 148 patients with clinically con®ned prostate cancer. Overall, the incidence of positive margins decreased from 37% to 18% (P`0.05). The decrease in positive margins was even greater in high-risk patients with pre-treatment PSA levels b 10 mg/l (63% vs 18%), suggesting that these men may be the most likely to bene®t from NHT. In the Belgian study, no difference in positive margin rates was observed using only 6 weeks of estramustine phosphate when all patients were considered (40.5 vs 46.5%); however, when only T 2 patients were considered, there was a statistically signi®cant decrease in positive margin disease. 32 The randomized studies reviewed using 3 months of NHT in Table 2 consistently report 90% decreases in serum PSA levels, 30% decreases in prostatic volume, 50% decreases in positive margin rates in cT 1 or cT 2 (but not cT 3 ) disease, higher organ-con®ned rates, and no differences in incidence of seminal vesicle involvement or positive lymph nodes.
Caution is required, however, when interpreting studies using pathologic stage as an endpoint despite the apparently encouraging results reviewed above. The ability of NHT to reduce biochemical and local recurrence remains the ultimate goal and this has not yet been determined. Soloway et al 37 recently reported 24 month follow-up data on 256 evaluable patients in the US Intergroup Study and found that 21% of the NHT group compared to 21.6% of the surgery alone group had PSA levels b 0.4 mg/l (P 0.473). Similarly, the CUOG study has not demonstrated any differences in PSA recurrence rates at 36 months follow-up, with recurrence rates of 35% and 40% in the control and NHT arms, respectively. 38 These two studies suggest that 3 months of NHT does not signi®cantly reduce the risk of treatment failure. There are, however, several possible reasons for lack of apparent difference in PSA recurrence rates despite favorable changes in positive margin rates. First, the sample size of these studies was based on detecting differences in positive margin rates, and therefore the studies were not large enough to have the statistical power necessary to detect signi®cant differences in biochemical recurrence rates. Second, follow-up is short and any bene®t from NHT may only become apparent after longer follow-up. Patterns of failure following radical prostatectomy suggest that early failures (ie`2 y) are more often distant, while most local failures (ie those most likely to be affected by short-term NHT), do not become manifest until 3 or more years after surgery. Third, approximately half the patients in these studies had low-risk tumors (Gleason 6, PSA 10 mg/l) with a very low risk of PSA recurrence after radical prostatectomy (10 ± 20%), which could dilute any potential bene®t from NHT. Finally, there may be a true lack of bene®t from 3 months of NHT, because of an error either in application (ie the duration of NHT was too short), or in concept (ie no matter how NHT is applied, it will not alter recurrence rates).
Androgen ablation therapy is rarely curative in patients with osseous metastases; however 10% of patients with D2 disease do survive for longer than 10 y after castration. Clinical observations further suggest that soft tissue disease responds more favorably to androgen ablation with more frequent and durable complete responses to compared to osseous metastases. 39, 40 Patients with stage D1 lymph node-only disease have a median survival more than twice that of patients with D2 osseous disease. 40 Adjuvant androgen ablation therapy following radical prostatectomy in patients with regional lymph node metastases results in long-term (15 y) survival in 30%, which suggests that a signi®cant proportion of patients with low volume soft tissue metastases may be cured with surgery and immediate androgen ablation. 41 One would anticipate that a similar proportion of patients with clinically localized tumors and unrecognized subclinical metastases who would ultimately recur after radical prostatectomy alone may also be cured by NHT as long as the course of therapy is long enough.
Clinical studies with long-term neoadjuvant therapy
The timing (in terms of initiation at the molecular/cellular level and completion at the tumor population level) of castration-induced apoptosis of prostate carcinoma cells remains poorly de®ned, but it is likely that castrationinduced apoptosis is an asynchronous event initiated at variable times in a heterogenous tumor population. Timing of apoptosis is dif®cult to characterize in human prostatic tumors because of the absense of appropriate of animal model systems, and because serial or comparative immunostaining of biopsies for apoptotic bodies inconsistently detects uncommon events that exist for relatively short periods of time. Although downsizing occurs after 3 months of NHT, serum PSA has not reached undetectable levels in most patients after this period of time. Ongoing decreases in serum PSA after the second month of therapy are not due to further decreases in PSA gene expression because changes in gene expression occur rapidly and reach basal levels shortly after testosterone reaches castrate levels. 42 Therefore, decreases in serum PSA after the second month possibly re¯ect an ongoing imbalance between apoptotic prostate epithelial cell death and decreased tumor cell proliferation, which leads to further reduction in tumor volume. These observations suggest that optimal duration of NHT may be longer than 3 months.
A prospective trial was initiated to study the biochemical and pathologic effects of 8 months of NHT prior to surgery in 156 men. 43, 44 Different rates of PSA decline after institution of therapy produces two distinct slopes a precipitous drop during the ®rst month and a more gradual subsequent decrease which continued into the eighth month of therapy (Figure 2 ). The initial rapid 80 ± 90% decrease in PSA during the ®rst month results from cessation of androgen-regulated PSA synthesis and apoptosis, while the ongoing slower 50% decline may parallel decreasing number of PSA-producing prostatic cells. Serum PSA decreases to undetectable levels or reaches nadir levels in 22% of patients after 3 months, 42% after 5 months and 84% after 8 months. After 8 months of NHT, serum PSA levels were 0.5 mg/l in 18% of patients 0.4 mg/l in 82% of patients,`0.3 mg/l in 76% of patients, and 0.2mg/l in 66%.
Most patients in this study had organ-con®ned, stage pT 2 tumors (79%), and half of these had microfoci or small volume tumors occupying less than 5% of the prostate (Table 3 ). The positive margin rate was 5.8%, lower than that reported after 3 months of NHT in similar cohorts of patients 34, 36, 37 (Figure 3) . No cancer was identi®ed in the radical prostatectomy specimen in 13% of cases. Microscopic extension through prostatic capsule with negative margins (pT 3 M-) was reported in 13% of the patients. Pathologic stage and risk of positive margins increased with higher clinical T-stage, grade and pretreatment serum PSA levels ( Table 3) . None of 65 patients with T 1c or T 2a tumors had positive margins compared to 7.5% of 79 with T 2b and 25% of 12 patients with T 3a disease. Positive margins were identi®ed in 2% of patients with Gleason scores 4, 5% with scores of 5 or 6, and 11% with Gleason scores of b 7. None of 99 patients with PSA levels`10 mg/l had positive margins, compared to 15% of 57 with PSA levels 10mg/l. Although patients with organ-con®ned tumors tended to have lower mean PSA Figure 2 Changes in serum PSA levels in men with clinically localized prostate cancer after initiation of 8 months of androgen withdrawal therapy. Neoadjuvant hormonal therapy ME Gleave et al nadir levels, the nadir PSA value was not predictive of pathologic stage in individual patients. Biochemical recurrences occurred in 19 patients (12.2%), most within the ®rst 2 y of surgery after a mean 52 months postoperative follow-up ( Figure 4A ). Risk of biochemical recurrence after 8 months of NHT remains proportional to known risk factors for recurrence, including pretreatment serum PSA and Gleason score, and pathologic stage ( Table 4 ). The PSA recurrence rate in this Phase II study using 8 months of NHT compares favorably with recurrence rates reported by the US Intergroup, 40 the Canadian Uro-Oncology Group, 41 the Cleveland Clinic, Washington University, 45 and Baylor College of Medicine 8 (Table 5) . Differences in PSA recurrence rates are most pronounced when only patients with high-risk features are considered (Table 5) .
Meyer et al 46 recently reviewed 680 men followed for 38 months after radical prostatectomy and reported an overall PSA failure rate of 33% at 5 y. Interestingly, patients who received neoadjuvant androgen ablation for longer than 3 months had a signi®cantly lower risk of PSA failure than those treated by radical prostatectomy alone (hazard ratio 0.52).
Apparent improvement in recurrence rates between uncontrolled studies from different centers must, however, be interpreted with caution. Any potential bene®t of (22) 12 (21) 3 (16) longer-term NHT is best con®rmed by Phase III studies, one of which has been recently initiated by the Canadian Uro-Oncology Group. CUOG-P95A randomized 547 men with clinically con®ned prostate cancer to either 3 or 8 months of leuprolide acetate and¯utamide prior to radical prostatectomy. 47 The study was powered to detect a 25% decrease in PSA recurrence, assuming a 30% recurrence in the 3 month arm after 3 y. Patients were equally strati®ed for clinical stage, Gleason grade and serum PSA. Interim analysis of biochemical and pathologic differences between the 3 and 8 month groups demonstrated signi®cant differences. Mean serum PSA decreased 89% to 0.12 mg/l after 3 months, with a further 53% to 0.056 mg/l from 3 to 8 months. Presurgery PSA nadir levels were`0.1 mg/l in 35% vs 73%, and 0.3 mg/l in 37% vs 10% after 3 vs 8 months, respectively. TRUS-determined prostatic volume decreased 37% from a mean of 40.5 cm 3 to 25.7 cm 3 after 3 months of NHT (P 0.0001) and a further 11% to 22.8 cm 3 after 8 months (P 0.03). Positive margin rates were 23% and 12% in the 3 and 8 month groups, respectively (P`0.01). This Phase III study con®rms that there is on-going biochemical and pathological regression of prostate tumors between 3 and 8 months of NHT, suggesting the optimal duration of NHT is longer than 3 months. Determination of whether longer therapy alters PSA recurrence rates must await longer follow-up.
Potential pitfalls of neoadjuvant therapy
Does NHT result in artifactual pathological understaging?
Following NHT, residual foci of atrophic glands can be dif®cult to identify with H&E staining, raising the possibility that pT-0 staging or low positive margin rates may be an artifact resulting from pathological understaging. Some authors argue that downsizing occurs without downstaging and any apparent downstaging results from dif®culty in pathologic evaluation of the NHTtreated prostatectomy specimen. 11 ± 13 Evidence thus far, however, overwhelming suggests that the NHT-induced decrease in positive margin rates is a real, rather than an artifactual, phenomenon. First, all randomized studies using a single central and experienced pathologist report similar (50%) decreases in positive margin rates (see Table 2 ). Second, reevaluation of prostatectomy specimens using prostatic acid phosphatase (PAP) and cytokeratin immunostaining to help identify foci of cancer dif®cult to see with H&E prepared sections did not signi®cantly increase positive margin rates. 43, 48 Third, animal model studies using androgen-dependent Shionogi tumors demonstrate that NHT reduces local recurrence and positive margin rates by 50%. 22 Finally, pathologic stage remains proportional to pre-treatment risk factors (serum PSA, T-stage and Gleason grade), and an important prognostic predictor for biochemical relapse 33,36,44 ( Figure 4B ). Taken together, these observations suggest that the changes in pathologic stage induced by NHT are real and not artifactual.
Is surgery more dif®cult following neoadjuvant therapy?
Concerns have been raised by some urologists that NHT makes surgery more dif®cult by increasing periprostatic adhesions. However, this does not appear to be the case. Randomized series that have documented surgical dif®-culty, blood loss, length of procedure, and postoperative complications found no signi®cant difference in these parameters between NHT-treated and untreated groups. 31, 33 Apoptosis initiated by androgen withdrawal (or other stimuli elsewhere throughout the organism) is a controlled cellular event that is not associated with acute in¯ammation or scarring. However, one technical factor after 8 months of NHT is that the prostate can decrease to a small, fusiform swelling of the urethra which can make it more dif®cult to palpate the prostatic apex and decide where to take the dorsal bundle.
Does tumor progression occur during prolonged NHT?
Because of possible risk of progression and outgrowth of androgen-independent clones during prolonged NHT, changes in levels of the proliferation marker Ki-67 and the oncoprotein Bcl-2 have been assessed. 43, 49 Ki-67 staining remained suppressed in most patients after 8 months of NHT. 43, 49 Similarly, staining for the cyclin-dependent kinase inhibitor, p27, increased in prostate cancer specimens after NHT ranging between 3 and 8 months. 50 These observations suggest cell cycle arrest is induced by androgen withdrawal in most residual cancer cells surviving NHT. Levels of the antiapoptotic oncoprotein, Bcl-2, increase during the ®rst 3 months of NHT, and remain elevated after 8 months of therapy, 49 consistent with its role in prevention of castration-induced apoptosis. 51, 52 Taken together, ongoing decreases in serum PSA, the high percentage of organ-con®ned and small-volume tumors, and the absence of increased PCNA and Ki-67 immunostaining suggest that progression from outgrowth of androgen-independent clones during prolonged NHT is unlikely.
Will recurrence rates be altered by neoadjuvant therapy?
With the exception of testis, low ano-rectal, and Wilm's tumors, most data do not support use of neoadjuvant therapies for most solid tumors when survival outcomes are compared to local therapy alone or followed by adjuvant therapy. Indeed, it remains possible that delay in de®nitive local therapy by neoadjuvant treatments may be detrimental. Lack of bene®t of neoadjuvant chemotherapy in other solid tumors, such as cervix, 53 small cell lung 54 and bladder, 55 illustrates that use of therapies capable of inducing complete responses may not have positive effects on survival when use in a neoadjuvant setting. Determining whether 3 months of NHT reduces recurrences after radical prostatectomy will have to await maturation of the recently completed Phase III studies 30 ± 36 (Table 2 ). However, it is critical to realize that the sample size of these studies was based on detecting differences in positive margin rates, and lacks suf®cient statistical power to detect smaller differences in biochemical recurrence rates. Whether longer-term NHT is any better is being evaluated by Phase III studies through CUOG. Until recurrence rates have been demonstrated to decrease in randomized studies, NHT should be considered investigational and studied in the context of controlled clinical studies.
